In a recent letter to the Delaware House of Representatives, the AMCP asked the body not to impose dollar limits on the prescription drug insurance practice of cost-sharing known as specialty tiers. The problem is not rooted in health plans’ management of specialty drugs, but in the way manufacturers are pricing these therapies, the AMCP letter stated. More here. (Source: Specialty Pharmacy Times, 7/16/13)
You are here: / AMCP to Delaware, please no price-related limits on specialty drugs!